b'LabPMM Assay GuidelinesMyAML is a targeted gene panel that analyzes the coding and non-coding exons of nearly 200 genes,For blood cancers other than AML, consider MyHEME.as well as the breakpoint hotspots within 36 genes. MyAML combines long read chemistry and deep sequencing with an optimized and validated custom bioinformatics pipeline, MyInformatics, to specificallyThe MyHEME NGS panel identifies clinically actionable, pathogenic, and potentially pathogenic mutations examine genomic variants in AML patients. in more than 700 genes associated with hematologic malignancies.Consider testing with Consider testing withoras an entry point intoor as an entry point into clinical trialsclinical trials or to optimize treatment B- and T-cell NPM1 clonality testing according to disorderPatient with suspected or FLT3 or Patient with suspected orconfirmed hematological LeukoStrat CDx FLT3 Mutation Assay confirmed AML diagnosis malignancyOur FLT3 ITD and NPM1 MRD testsFollow-up with MRD assays unique for Follow-up with MRD assays unique forbiomarkers identified in each patient, such are amplicon-based NGS assays,biomarkers identified in each patient, suchas IGH, IGK, TRG, TRB andwith a limit of detection of 5x10 -5 as FLT3 ITD MRD, NPM1 MRD and The MyMRD is a NGS-based panel that assesses variants in hotspots from 23 genes that commonly drive myeloid malignancies, including AML, MPN and MDS. It can detect SNVs, indels, and translocations to the genomic basepair, offering unparalleled precision and detection of low level mutations in patients. The MyMRD assay detects at least one driver mutation in 90%-95% of all AMLs.MyAML and MyMRD are CLIA validated assays. MyHEME is Research Use Only (RUO).10 LabPMM Services Catalog 2020|11'